2022 Guide to Patient Support Services

Agios Pharmaceuticals

Agios Pharmaceuticals myAgios Patient Support Services

844-409-1141

Agios Pharmaceuticals offers the myAgios Patient Support Services program to help patients with access and financial assistance when prescribed Tibsovo (Table).

myAgios Patient Support Services

The myAgios Patient Support Services program can help your patients with access to Tibsovo through the Commercial $25 Co-Pay Program, Patient Assistance Program, QuickStart Program, and the Coverage Interruption Program.

Commercial $25 Co-Pay Program

This program lowers costs for eligible patients to no more than $25 per prescription if their copay exceeds that amount, with a maximum benefit of $25,000 per calendar year. Patients may be eligible if they:

  • Have commercial insurance
  • Are NOT participating in government healthcare programs.

Patient Assistance Program

The Patient Assistance Program offers free prescriptions to eligible uninsured or underinsured patients and may apply to patients with commercial or state/government insurance. To be eligible, patients must:

  • Meet specified financial requirements
  • Have a home address in the United States or Puerto Rico.

QuickStart Program

The QuickStart Program provides a free 30-day prescription (allowing for 1 refill, for a total of 60 days) to eligible new patients experiencing coverage delays of 5 or more business days after submission of a completed prior authorization. Patients may be eligible if they:

  • Have commercial or government insurance coverage that has been delayed by 5 or more business days
  • Are naive to treatment
  • Reside in the United States or Puerto Rico
  • Fall into 1 of the 3 following categories:
    • Newly diagnosed with acute myeloid leukemia (AML) and aged ≥75 years, or
    • Newly diagnosed with AML and have comorbidities that preclude use of intensive induction chemotherapy, or
    • Relapsed or refractory AML.

Coverage Interruption Program

The Coverage Interruption Program provides a free 30-day prescription (allowing for 2 refills, for a total of 90 days) to eligible new patients experiencing an interruption in coverage. Patients participating in government and state healthcare insurance are not eligible. Patients may be eligible if they:

  • Have a home address in the United States or Puerto Rico
  • Are currently taking Tibsovo, with at least 1 prior commercial insurance dispense.

Click here to enroll your patient in the Commercial $25 Co-Pay Program. To enroll your patient in the Patient Assistance Program, QuickStart Program, or the Coverage Interruption Program, complete the appropriate sections of the myAgios enrollment form and fax to 844-409-1143.

TABLE Agios Oncology Drug

Drug
Indications
Patient support programs

Drug
Tibsovo (ivosidenib tablets)
Indications
Treatment of newly diagnosed AML with a susceptible IDH1 mutation, as detected by an FDA-approved test, in adults aged ≥75 years or those who have comorbidities that preclude use of intensive induction chemotherapy; treatment of adults with relapsed or refractory AML and IDH1 mutation, as detected by an FDA-approved test; treatment of adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma and IDH1 mutation, as detected by an FDA-approved test
Patient support programs

AML indicates acute myeloid leukemia.

Report Broken Links

Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?

Help us fix it! Report broken links here.

Report Broken Links

Report Broken Links

*OPM Webpage
Please copy the URL (link) of the OPM webpage you are currently on.
*Broken Link
Please copy the URL (link) to the external webpage that is not displaying content correctly.
Errors include, but are not limited to:
  • "This site can’t be reached"
  • "Hmm. We’re having trouble finding that site."
  • "Hmmm… can't reach this page"
  • "404 Error: Page not found"
Comments
(Optional)